Extract
Pulmonary arterial hypertension (PAH) is a rare disease characterised by remodelling of small pulmonary vessels, which results in a progressive increase in right ventricular afterload [1]. Most of the symptoms and signs of PAH are attributable to impaired right heart function. However, patients with PAH also show variable alterations of their lung diffusion capacity for carbon monoxide (DLCO) and gas exchange, which contribute to disease symptoms and severity.
Tweetable abstract
Sotatercept may improve lung diffusion capacity for carbon monoxide and oxygenation in patients with pulmonary arterial hypertension https://bit.ly/3PUUmjw
Acknowledgements
We are indebted to Susanne Tayler, Nicole Wintzenburg, Franziska Zetzsche, and Nicole Shearman (all from the Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany) for their invaluable support during the studies.
Footnotes
Conflict of interest: K.M. Olsson has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, Ferrer, GSK, Janssen, MSD, Pfizer and United Therapeutics. J. Fuge has received personal fees/speaker honoraria from AstraZeneca, outside the submitted work. D-H. Park is supported by PRACTIS – Clinician Scientist Program at Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3-1). J.C. Kamp is supported by PRACTIS – Clinician Scientist Program at Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3-1). T. Brod has no disclosures. B. Harrigfeld has no disclosures. J.C. Schupp has patents on new therapies in pulmonary fibrosis and has received lecture fees from Boehringer Ingelheim. M.M. Hoeper reports fees for lectures and/or consultations from Acceleron, Actelion, Altavant, AOP Health, Bayer, Ferrer, Janssen and MSD, and has a patent application filed by MSD for US patent application number 63466014, entitled “Methods of improving lung diffusion capacity in a patient with pulmonary arterial hypertension”.
Support statement: The PULSAR and STELLAR trials were funded by Acceleron Pharma, a subsidiary of MSD. These companies were not involved in the present analysis and did not contribute to the manuscript. However, the manuscript underwent a legal review by MSD prior to submission, which resulted in an US patent application (number 63466014) entitled “Methods of improving lung diffusion capacity in a patient with pulmonary arterial hypertension” where M.M. Hoeper is listed as inventor.
- Received May 17, 2023.
- Accepted July 8, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
